Women taking HT had a significantly decreased incidence of fracture with long-term use .
Research ers found no strong evidence that HT has a clinical ly meaningful impact on the incidence of colorectal cancer .
AUTHORS ' CONCLUSIONS : Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT , provided they do not have specific contraindications .
HT may be unsuitable for some women , including those at increased risk of cardiovascular disease , increased risk of thromboembolic disease ( such as those with obesity or a history of venous thrombosis ) or increased risk of some types of cancer ( such as breast cancer , in women with a uterus ) .
The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well documented .
HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia , nor for prevention of deterioration of cognitive function in postmenopausal women .
Although HT is considered effective for the prevention of postmenopausal osteoporosis , it is generally recommended as an option only for women at significant risk for whom non-oestrogen therapies are unsuitable .
BACKGROUND : Hormone therapy ( HT ) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease , osteoporosis and  dementia in older women .
This is an up date d version of a Cochrane review first published in 2005 .
OBJECTIVES : To assess effects of long-term HT ( at least 1 year 's duration ) on mortality , cardiovascular outcomes , cancer , gallbladder disease , fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment .
Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.
BACKGROUND In the Women 's Health Initiative ( WHI ) r and omized controlled trial , use of estrogen plus progestin increased  lung cancer mortality . We conducted post hoc analyses in the WHI trial evaluating estrogen alone to determine whether use of conjugated equine estrogen without progestin had a similar adverse influence on lung cancer . METHODS The WHI study is a r and omized , double-blind , placebo-controlled trial conducted in 40 centers in the United States . A total of 10 739 postmenopausal women aged 50 - 79 years who had a previous hysterectomy were r and omly assigned to receive a once-daily 0.625-mg tablet of conjugated equine estrogen ( n = 5310 ) or matching placebo ( n = 5429 ) . Incidence and mortality rates for all lung cancers , small cell lung cancers , and non-small cell lung cancers in the two r and omization groups were compared by use of hazard ratios ( HRs ) and 95 % confidence intervals ( CIs ) that were estimated from Cox proportional hazards regression analyses . Analyses were by intention to treat , and all statistical tests were two-sided . RESULTS After a mean of 7.9 years ( st and ard deviation = 1.8 years ) of follow-up , 61 women in the hormone therapy group were diagnosed with lung cancer compared with 54 in the placebo group ( incidence of lung cancer per year = 0.15 % vs 0.13 % , respectively ; HR of incidence = 1.17 , 95 % CI = 0.81 to 1.69 , P = .39 ) . Non-small cell lung cancers were of comparable number , stage , and grade in both groups . Deaths from lung cancer did not differ between the two groups ( 34 vs 33 deaths in estrogen and placebo groups , respectively ; HR of death = 1.07 , 95 % CI = 0.66 to 1.72 , P = .79 ) . CONCLUSION Unlike use of estrogen plus progestin , which increased deaths from lung cancer , use of conjugated equine estrogen alone did not increase incidence or death from lung cancer
Women taking HT had a significantly decreased incidence of fracture with long-term use .
Research ers found no strong evidence that HT has a clinical ly meaningful impact on the incidence of colorectal cancer .
AUTHORS ' CONCLUSIONS : Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT , provided they do not have specific contraindications .
HT may be unsuitable for some women , including those at increased risk of cardiovascular disease , increased risk of thromboembolic disease ( such as those with obesity or a history of venous thrombosis ) or increased risk of some types of cancer ( such as breast cancer , in women with a uterus ) .
The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well documented .
HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia , nor for prevention of deterioration of cognitive function in postmenopausal women .
Although HT is considered effective for the prevention of postmenopausal osteoporosis , it is generally recommended as an option only for women at significant risk for whom non-oestrogen therapies are unsuitable .
BACKGROUND : Hormone therapy ( HT ) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease , osteoporosis and  dementia in older women .
This is an up date d version of a Cochrane review first published in 2005 .
OBJECTIVES : To assess effects of long-term HT ( at least 1 year 's duration ) on mortality , cardiovascular outcomes , cancer , gallbladder disease , fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment .